Skip to main content

Table 2 Annual and cumulative estimated HCV treatment uptake in Norway and Sweden among OAT patients 2014–2017

From: Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

  2014 2015 2016 2017
Country Norway Sweden Norway Sweden Norway Sweden Norway Sweden
HCV treatment n (overall) 148 54 178 105 216 124 378 124
Study population n, 6057 2663 6005 2640 5537 2683 5545 2739
HCV treatment % (95% CI) 2.4 (2.1–2.8) 2.0 (1.5–2.6) 3.0 (2.5–3.4) 4.0 (3.2–4.7) 3.9 (3.4–4.4) 4.6 (3.8–5.4) 6.8 (6.2–7.5) 4.5 (3.8–5.3)
Expected proportion of OAT patients who are not PWID, na 303 133 300 132 276 134 277 137
Expected Anti-HCV, weighted by PWID status, nb 4651 2075 4612 2057 4252 2091 4258 2135
Expected chronic HCV after spontaneous clearance, n (UI)c 3442 (3303–3628) 1536 (1474–1619) 3413 (3274–3597) 1523 (1461–1605) 3147 (3019–3317) 1547 (1485–1631) 3151 (3023–3321) 1580 (1516–1665)
Expected chronic HCV after treatment, n (UI) 3294 (3155–3480) 1482 (1420–1565) 3235 (3096–3419) 1418 (1356–1500) 2931 (2803–3101) 1423 (1361–1507) 2773 (2645–2943) 1456 (1392–1541)
Expected chronic HCV after spontaneous clerance and treatment, % (UI) 54.4 (52.1–57.5) 55.6 (53.3–58.8) 53.9 (51.6–56.9) 53.7 (51.4–56.8) 52.9 (50.6–56.0) 53.1 (50.7–56.2) 50.0 (47.7–53.1) 53.1 (50.8–56.3)
Estimated HCV treatment uptake % (UI) 4.5 (4.3–4.7) 3.6 (3.5–3.8) 5.5 (5.2–5.7) 7.4 (7.0–7.7) 7.4 (7.0–7.7) 8.7 (8.2–9.1) 13.6 (12.8–14.3) 8.5 (8.0–8.9)
Estimated HCV cumulative treatment uptake % (UI) 4.5 (4.3–4.7) 3.6 (3.5–3.8) 10.0 (9.5–10.4) 11.1 (10.5–11.5) 17.4 (16.4–18.1) 19.8 (18.7–20.7) 31.0 (29.3–32.4) 28.3 (26.7–29.6)
  1. Sources: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD), Intro-HCV = Integrated treatment of hepatitis C study, Kåberg et al. [24]: Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program
  2. Micallef et al. [27]: Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.
  3. OAT Opioid agonist therapy, HCV Hepatitis C virus infection, CI Confidence interval, UI Uncertainty interval
  4. Anti-HCV Antibodies to hepatitis C virus, PWID People who inject drugs
  5. aExpected non-PWIDs among OAT patients set to 5%
  6. bExpected Anti-HCV among PWID in Norway 80.8%, expected Anti-HCV among PWID in Sweden 82%, expected Anti-HCV among non-PWID in both Norway and Sweden is 0.7%
  7. cExpected spontaneous clearance 26% (22–29%)
  8. For more comprehensive details on sources and model calculation, see Additional file 1